Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol

  title={Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol},
  author={Walter L. Miller},
  journal={Hormone Research in Paediatrics},
  pages={416 - 420}
  • W. Miller
  • Published 26 August 2019
  • Medicine, Biology
  • Hormone Research in Paediatrics
Congenital adrenal hyperplasia (CAH) due to steroid 21-hydroxylase deficiency (21OHD) has a worldwide incidence of 1 in 15–20,000. Affected individuals have adrenal insufficiency and androgen excess; the androgen excess begins during fetal life, typically resulting in 46,XX disordered sexual development. In 21OHD, 17-hydroxyprogesterone (17OHP), the steroid proximal to 21-hydroxylase, accumulates. Most industrialized countries have newborn screening programs that measure 17OHP; such screening… 

Figures from this paper

Neonatal Screening and Genotype-Phenotype Correlation of 21-Hydroxylase Deficiency in the Chinese Population
It is suggested that neonatal screening effectively leads to the early diagnosis of 21-OHD and reduces fatal adrenal crisis.
Congenital adrenal hyperplasia - current insights in pathophysiology, diagnostics and management.
Current insights in congenital adrenal hyperplasia are provided with special attention to more detailed understanding of steroidogenic pathways, refinements in neonatal screening, improved diagnostic measurements utilizing chromatography and mass spectrometry coupled with steroid profiling, and improved genotyping methods.
Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy
The pathology of 21OHD is summarized and also the key stages of fetal hypothalamic-pituitary-adrenal axis development and adrenal steroidogenesis that contribute to limitations in screening accuracy are summarized.
Thirty-Year Lessons from the Newborn Screening for Congenital Adrenal Hyperplasia (CAH) in Japan
The experience of the past 30 years of the NBS for CAH in Japan is summarized, composed of four parts, 1: screening system in Japan, 2: the clinical outcomes for the patients with CAH, 3: various factors that would impact the N BS system, including timeline, false positive, and LC-MS/MS, and 4: Database composition and improvement of the screening program.
Premature adrenarche in girls is characterized by enhanced 17,20-lyase and 17β-hydroxysteroid dehydrogenase activities.
Girls with premature adrenarche may have a higher risk to develop polycystic ovary syndrome (PCOS) and metabolic syndrome and Prospective studies should assess whether steroid production in PA also differs from adrenarches at normal timing and persists into adulthood.
11-Oxygenated Androgens Useful in the Setting of Discrepant Conventional Biomarkers in 21-Hydroxylase Deficiency.
11-Oxyandrogens, especially 11-hydroxytestosterone, may be useful in the management of CAH when conventional biomarkers are inconclusive, and provided the best discrimination between poor vs good control.
Outcome of Newborn Screening for Congenital Adrenal Hyperplasia at Two Time Points
Early collection of specimens necessitated by early discharge resulted in milder CAH cases falling below the screening 17-OHP cutoff, and 21-Hydroxylase genotypes overlapped in first versus second screen cases.
Androgen excess and diagnostic steroid biomarkers for nonclassic 21-hydroxylase deficiency without cosyntropin stimulation.
Adrenal 11-oxyandrogens are disproportionately elevated compared to conventional androgens in N21OHD, and Steroid panels can accurately diagnose N 21OHD in unstimulated blood tests.
Disorders of Sex Development of Adrenal Origin
The pathophysiology, clinical presentation and management of the above-mentioned disorders are critically reviewed, with a special focus on the latest biomarkers and therapeutic development.


Serum 21-Deoxycortisol, 17-Hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11beta-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency.
To recognize patients with 21- and/or 11betaOHD, patients with congenital adrenal hyperplasia should consider evaluation of 17OHP or 21DF and S, and 21DF may be useful to follow up pubertal Patients with 21OHD.
Elevated 17-hydroxyprogesterone and testosterone in a newborn with 3-beta-hydroxysteroid dehydrogenase deficiency.
Congenital adrenal hyperplasia is the most frequent cause of ambiguous genitalia and adrenal insufficiency in newborn infants and a deficiency of 11-hydroxylase or of 3-beta-hydroxysteroid dehydrogenase (3-β-HSD) is diagnosed by the finding of elevated serum concentrations of11-deoxycortisol or 17-Hydroxypregnenolone.
Difficulties in the diagnosis of congenital adrenal hyperplasia in early infancy: the 11 beta-hydroxylase defect.
Investigations of steroid metabolism in a newborn infant with steroid 11 beta-hydroxylase deficiency are described, where in the first days of life the excretion of cortisol was low but most other hormonal parameters were normal and the major metabolite of 11-deoxycortisol (tetrahydro-S, THS) was not detectable in the urine.
Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia
The findings confirm the benefits of newborn screening for CAH and the importance of a second screening test, and suggest that programs for newborn CAH screening must consider complex issues in diagnosis and treatment.
Neonatal Screening: Identification of Children with 11β-Hydroxylase Deficiency by Second-Tier Testing
Steroid profiling in newborn blood samples showing positive results in immunoassays for 17-OHP allows for differentiating 21-OHD from 11-O HD, the target disease of newborn screening for congenital adrenal hyperplasia (CAH).
Prenatal diagnosis of 21-hydroxylase deficiency congenital adrenal hyperplasia by simultaneous radioimmunoassay of 21-deoxycortisol and 17-hydroxyprogesterone in amniotic fluid.
Simultaneous measurement of 21-DOF and 17-OHP levels in amniotic fluid from 10-18 weeks of gestation can be used for early diagnosis of congenital adrenal hyperplasia.
Serum 21-deoxycortisol and 17-hydroxypregnenolone in parents of patients with congenital adrenal hyperplasia
The rate of increase of 21-DF from 0 to 60 min following ACTH provides a method for the detection of some heterozygote carriers of congenital adrenal hyperplasia and may be useful particularly in the identification of female carriers.
Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
The authors' liquid chromatography-tandem mass spectrometry procedure as a second-tier test can be used to reduce false-positive results of standard 21-CAH screening, and was proven to proven within a range of 5-100 nmol/liter.
Genotyping steroid 21-hydroxylase deficiency: hormonal reference data.
Hormonal reference data, in the form of nomograms relating baseline and stimulated levels of adrenal hormones, provide a means of genotyping steroid 21-hydroxylase (21-OH) deficiency in congenital adrenal hyperplasia and provide a powerful tool by which to assign the 21-OH deficiency genotype.
Plasma steroids in congenital adrenal hyperplasia.
In contrast to 17-hydroxyprogesterone, which was elevated as much as 100-fold, the Δ5-steroids were elevated only about 2-fold when compared to normal adult values, in contrast to the 21-hydroxylase deficiency type of congenital adrenal hyperplasia.